If ongoing studies demonstrate favorable safety and efficacy profiles, CAR T-cell therapy may establish a novel treatment ...
Ocrelizumab is associated with increased risks for infection and hospitalization among older adults with multiple sclerosis, ...
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS ...
A Journal of Neurology case report describes severe invasive pneumococcal pneumonia after influenza A in a multiple sclerosis ...
A longitudinal study of early relapsing–remitting multiple sclerosis finds that paramagnetic rim lesions and enlarged choroid ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing ...
A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis. The results are striking because existing MS treatments ...
Multiple Sclerosis (MS) imposes a significant psychological burden that adversely affects patients’ subjective well-being (SWB). A primary psychological stressor in this population is the Fear of ...
2don MSN
Exclusive: Thermo Fisher to support Quantum Biopharma in progressive multiple sclerosis drug trial
Quantum BioPharma Ltd. QNTM on Tuesday said it is partnering with the clinical research division of Thermo Fisher Scientific ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma ”), a biopharmaceutical company focused on developing ...
Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, ...
WALTHAM - Zenas BioPharma, Inc. ('Zenas' or the 'Company') (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results